Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Verina

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Seminars in Oncology Nursing|July 18, 2017
Young Adults with Multiple MyelomaHollie Devine, Daniel Verina
Journal of the Advanced Practitioner in Oncology|August 8, 2022
A Focus on Newly Diagnosed Multiple MyelomaKevin Brigle, Daniel Verina, Beth Faiman
Clinical Journal of Oncology Nursing|September 26, 2017
Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma
Kimberly Noonan, Sandra Rome, Beth Faiman, et al.
Therapeutic Advances in Hematology|February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myelomaLarysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Journal of Hematology & Oncology|August 17, 2022
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutationMuhammad Elnaggar, Sarita Agte, Paula Restrepo, et al.
Blood Advances|January 4, 2018
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaAjai Chari, Hearn J Cho, Amishi Dhadwal, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Seminars in Oncology Nursing|July 18, 2017
Young Adults with Multiple MyelomaHollie Devine, Daniel Verina
Journal of the Advanced Practitioner in Oncology|August 8, 2022
A Focus on Newly Diagnosed Multiple MyelomaKevin Brigle, Daniel Verina, Beth Faiman
Clinical Journal of Oncology Nursing|September 26, 2017
Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma
Kimberly Noonan, Sandra Rome, Beth Faiman, et al.
Therapeutic Advances in Hematology|February 22, 2021
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myelomaLarysa Sanchez, Joshua Richter, Hearn Jay Cho, et al.
Journal of Hematology & Oncology|August 17, 2022
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutationMuhammad Elnaggar, Sarita Agte, Paula Restrepo, et al.
Blood Advances|January 4, 2018
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaAjai Chari, Hearn J Cho, Amishi Dhadwal, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Pageof 1